QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) 期刊论文 CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885 作者:  Wu, Jiaxin;  Wang, Aoli;  Li, Xixiang;  Chen, Cheng;  Qi, Ziping 收藏  |  浏览/下载：29/0  |  提交时间：2019/11/27 BCR-ABL  PDGFR  chronic myeloid leukemia  kinase inhibitor   Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade 期刊论文 CELLULAR SIGNALLING, 2019, 卷号: 63 作者:  Yin, Xiaolin;  Zhou, Minran;  Fu, Yue;  Yang, Lin;  Xu, Man 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/11 RBP2  Cell proliferation  CML  Crisis blast  BCR-ABL  PTEN   MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells 期刊论文 BIOMEDICINE & PHARMACOTHERAPY, 2019, 卷号: 112, 页码: 108623 作者:  Ma, Jichun[1];  Wu, Dehong[2];  Yi, Jing[3];  Yi, Yunyun[4];  Zhu, Xin[5] 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/24 MiR-378  K562 cell  Pluripotence  CML   Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety 期刊论文 2019, 卷号: 13, 期号: 3, 页码: 344-353 作者:  Huang, Xiaojun;  Jiang, Qian;  Hu, Jianda;  Li, Jianyong;  Jin, Jie 收藏  |  浏览/下载：15/0  |  提交时间：2020/01/03 chronic myeloid leukemia (CML)  dasatinib  tyrosine kinase inhibitor  long-term follow-up